Logo for University of Iowa Health Care This logo represents the University of Iowa Health Care


Currently Enrolling

If you're interested in participating or would like to learn more, please contact our study coordinator:

Karen Ekstam Smith

(319) 353-5158



The VIVA-MIND Study is a Phase 2 national multi-site clinical trial testing an investigational drug called Varoglutamstat (PQ912) for people who are age 50-89, and experiencing significant memory concerns, or who have already been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer’s disease (AD). This stage of the disease, MCI through mild AD disease, is also known as early AD.  The trial is designed to determine if the study drug may delay or slow the progression of the symptoms of early Alzheimer’s disease. 

Learn More



The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a landmark study that began in 2004, is a public-private research partnership tasked with identifying biomarkers to detect Alzheimer’s disease (AD). The study has gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF) and was designed to enable researchers to follow AD as it progresses in an individual, from various points in the disease process.  ADNI3 will include 600 new participants age 55-90 and 600 rollover participants from ADNI2.

Click here for more information 

Recently Completed Studies


The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the A4 Study) is a clinical trial for adults ages 65-85 who have normal thinking and memory function but who may be at risk for Alzheimer’s due to family history of the disease and elevated levels of amyloid plaque in the brain. The study aims to prevent the memory loss associated with the disease.


The purpose of the Memory Improvement Through Nicotine Dosing (MIND) study is to determine whether daily transdermal nicotine (patch) will have a positive effect on early memory impairment in participants diagnosed with Mild Cognitive Impairment (MCI).

T2 Protect AD 

The T2 Protect AD Study is a national multi-site clinical trial testing an investigational drug for people with mild to moderate Alzheimer’s disease (AD). The trial is designed to determine if the study drug can protect against, or slow down, memory and thinking problems that increase as Alzheimer’s disease progresses.


The CONNECT study is testing whether an oral, experimental drug, AZD0530 (saracatinib), will slow progression in early stage Alzheimer’s disease (AD). In its early stage after the medical diagnosis of Alzheimer’s disease, patients typically show some memory loss but a majority of daily functions are intact, requiring some reminders or help organizing the day from others in the household.


The purpose of ADNI2 is to examine how brain imaging and other biomarkers can be used to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease. The overall goals are increased knowledge concerning the sequence and timing of events leading to MCI and Alzheimer's disease, better methods for early detection of these conditions, and data that informs clinical trials aimed at slowing disease progression.


This Phase II study will evaluate the efficacy of the experimental drug T-817MA as a possible treatment for people with mild to moderate Alzheimer's disease. Participants will take tests to determine the drug's effects on memory, other aspects of cognition, and daily functioning. Physical exams, blood tests, and brain scans (MRI) will also be done.